4. 1. Box, G. Lucas, H. Design, . Of, . In-non-linear et al., The use of prior distributions in the design of experiments for 450 parameter estimation in non-linear situations: multiresponse case, Biometrika. 448 Biometrika, vol.4654, issue.23, pp.77-90662, 1959.

A. Atkinson and W. Hunter, The Design of Experiments for Parameter Estimation, Technometrics, vol.17, issue.2, p.453
DOI : 10.1080/00401706.1968.10490560

A. Atkinson and A. Donev, Optimum Experimental Design, 457 6. D'Argenio DZ. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems 458
DOI : 10.1007/978-3-642-04898-2_434

V. Fedorov and S. Leonov, Optimal Design for Nonlinear Response Models, Boca Raton, p.460

E. Landaw, Optimal design for individual parameter estimation in pharmacokinetics

L. Pronzato and E. Walter, Robust experimental design via maximin optimization, Math Biosci, vol.46489, issue.465, pp.161-76, 1988.
DOI : 10.1016/0025-5564(88)90097-1

S. Hennig, J. Nyberg, S. Fanta, J. Backman, K. Hoppu et al., Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin, The Journal of Clinical Pharmacology, vol.39, issue.3, pp.347-60, 2012.
DOI : 10.1177/0091270010397731

Y. Merle, F. Mentre, A. Mallet, and A. Aurengo, Designing an optimal experiment for Bayesian 469 estimation: application to the kinetics of iodine thyroid uptake, Stat Med. Epub, vol.1330, issue.471, pp.185-96, 1994.

L. Sheiner and S. Beal, Evaluation of methods for estimating population pharmacokinetic 472 parameters. III. Monoexponential model: routine clinical pharmacokinetic data, J Pharmacokinet, p.473

M. Al-banna, A. Kelman, and B. Whiting, Experimental design and efficient parameter estimation in population pharmacokinetics, Journal of Pharmacokinetics and Biopharmaceutics, vol.46, issue.4, pp.347-60, 1990.
DOI : 10.1007/BF01062273

E. Ette, A. Kelman, C. Howie, and B. Whiting, Analysis of animal pharmacokinetic data, p.477

E. Jonsson, J. Wade, and M. Karlsson, Comparison of some practical sampling strategies for population pharmacokinetic studies, Journal of Pharmacokinetics and Biopharmaceutics, vol.19, issue.2, pp.245-63, 1996.
DOI : 10.1007/BF02353491

E. Ette, H. Sun, and T. Ludden, Balanced designs in longitudinal population pharmacokinetic 482 studies, 483 17. U.S. Department of Health and Human Services FaDA. Guidance for Industry, pp.417-440, 1998.

F. Mentré, A. Mallet, and D. Baccar, Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, p.486
DOI : 10.1093/biomet/84.2.429

D. Cox, Biometrika: One Hundred Years, Biometrika, vol.84, issue.20, pp.429-471, 1997.

S. Retout, S. Duffull, and F. Mentre, Development and implementation of the population Fisher 490 information matrix for the evaluation of population pharmacokinetic designs, Comput Methods, p.491

S. Duffull, T. Waterhouse, and J. Eccleston, Some considerations on the design of population 493

M. Foracchia, A. Hooker, P. Vicini, A. Ruggeri, I. Gueorguieva et al., POPED, a software for optimal experiment design 495 in population kinetics Comput Meth Prog Bio A program for individual and 497 population optimal design for univariate and multivariate response pharmacokinetic- 498 pharmacodynamic models, Comput Methods Programs Biomed, vol.7486, issue.499, pp.29-4651, 2004.

A. Aliev, V. Fedorov, S. Leonov, B. Mchugh, and M. Magee, PkStaMp Library for Constructing Optimal 500

F. Mentré, M. Chenel, E. Comets, J. Grevel, A. Hooker et al., Current use and 502 developments needed for optimal design in pharmacometrics : a study performed amongst 503

I. Gueorguieva, L. Aarons, K. Ogungbenro, K. Jorga, T. Rodgers et al., DDMoRe's EFPIA members. 2012. 504 26, p.505

J. Nyberg, S. Ueckert, E. Stromberg, S. Hennig, M. Karlsson et al., PopED: an extended, 508 parallelized, nonlinear mixed effects models optimal design tool Comput Methods Programs 509

R. Gagnon and S. Leonov, OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING, Journal of Biopharmaceutical Statistics, vol.13, issue.1, p.511
DOI : 10.1002/0471725315

K. Ogungbenro, G. Graham, I. Gueorguieva, and L. Aarons, Incorporating correlation in 513 interindividual variability for the optimal design of multiresponse pharmacokinetic experiments, Biopharm Stat. J, vol.1511, issue.514, pp.143-63, 2005.

S. Retout and F. Mentré, Further developments of the Fisher information matrix in nonlinear 516 mixed effects models with evaluation in population pharmacokinetics, J Biopharm Stat, vol.51713, issue.518, pp.209-236, 2003.

M. Foracchia, A. Hooker, P. Vicini, and A. Ruggeri, poped, a software for optimal experiment design in population kinetics, Computer Methods and Programs in Biomedicine, vol.74, issue.1, pp.29-46, 2004.
DOI : 10.1016/S0169-2607(03)00073-7

S. Leonov and A. Aliev, Optimal design for population pk/pd models, Tatra Mountains Mathematical Publications, vol.51, issue.1, pp.115-145, 2012.
DOI : 10.2478/v10127-012-0012-1

T. Mielke and S. Schwabe, Some Considerations on the Fisher Information in Nonlinear Mixed 523

A. Berlinreilly, R. Aggeler, P. Leong, L. Studies, . On et al., 525 34, J Clin Invest, vol.42, issue.527, pp.129-165, 1963.

C. Bazzoli, S. Retout, and F. Mentre, Design evaluation and optimisation in multiple response 528

S. Retout, E. Comets, A. Samson, and F. Mentre, Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, p.532
DOI : 10.1002/sim.2910
URL : https://hal.archives-ouvertes.fr/hal-00263513

R. Reilly and P. Aggeler, Studies on coumarin anticoagulant drugs. Initiation of warfarin 534 therapy without a loading dose, Stat Med. Circulation, vol.2638, issue.535, pp.5162-7905, 1968.

J. Guedj, C. Bazzoli, A. Neumann, and F. Mentre, Design evaluation and optimization for models of hepatitis C viral dynamics, Statistics in Medicine, vol.38, issue.18, pp.1045-5602, 2011.
DOI : 10.1002/sim.4191
URL : https://hal.archives-ouvertes.fr/inserm-00615142

A. Neumann, N. Lam, H. Dahari, D. Gretch, T. Wiley et al., Hepatitis C viral 538 dynamics in vivo and the antiviral efficacy of interferon-alpha therapy, Science, vol.53928210, issue.5386, pp.103-702, 1998.